SXTC
China SXT Pharmaceuticals, Inc.
Drug Manufacturers - Specialty & Generic
Market Cap$671K
5Y Perf.-100.0%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
SXTC vs CHNR
Revenue, margins, valuation, and 5-year total return — side by side.
CHNR
China Natural Resources, Inc.
Waste Management
Market Cap$42M
5Y Perf.-86.7%
SXTC vs CHNR — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | SXTC | CHNR |
|---|---|---|
| Industry | Drug Manufacturers - Specialty & Generic | Waste Management |
| Market Cap | $671K | $42M |
| Revenue (TTM) | $2M | $0.00 |
| Net Income (TTM) | $-3M | $-14M |
| Gross Margin | 21.1% | — |
| Operating Margin | -154.0% | — |
| Total Debt | $984K | $0.00 |
| Cash & Equiv. | $18M | $3M |
SXTC vs CHNR — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
SXTC
CHNR
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| China SXT Pharmaceu… (SXTC) | 100 | 0.0 | -100.0% |
| China Natural Resou… (CHNR) | 100 | 13.3 | -86.7% |
Price return only. Dividends and distributions are not included.
Quick Verdict: SXTC vs CHNR
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: CHNR leads in 4 of 6 categories, making it the strongest pick for profitability and margin quality and capital preservation and lower volatility. China SXT Pharmaceuticals, Inc. is the stronger pick specifically for growth and revenue expansion. This set spans 2 sectors — these stocks serve different portfolio roles, not just different price points.
SXTC
China SXT Pharmaceuticals, Inc.
The Growth Play
SXTC is the clearest fit if your priority is growth exposure.
- Rev growth -9.7%, EPS growth -129.1%, 3Y rev CAGR -12.5%
- -9.7% revenue growth vs CHNR's -100.0%
Best for: growth exposure
CHNR
China Natural Resources, Inc.
The Income Pick
CHNR carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.
- Dividend streak 0 yrs, beta 1.12
- -93.5% 10Y total return vs SXTC's -100.0%
- Lower volatility, beta 1.12, current ratio 0.25x
Best for: income & stability and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | SXTC | -9.7% revenue growth vs CHNR's -100.0% |
| Quality / Margins | CHNR | 0.0% margin vs SXTC's -189.8% |
| Stability / Safety | CHNR | Beta 1.12 vs SXTC's 1.16 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | CHNR | -2.3% vs SXTC's -99.4% |
| Efficiency (ROA) | CHNR | -5.3% ROA vs SXTC's -15.2%, ROIC -0.0% vs -142.0% |
SXTC vs CHNR — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLCHNRLAGGINGSXTC
SXTCChina SXT Pharmaceuti…
0leads
CHNRChina Natural Resourc…
4leads
6 Total Categories
CATEGORYLEADERvs SXTCMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
CHNR1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
CHNR5/8
Total Returns1Y, 3Y, 5Y total returns with dividends
CHNR6/6
Risk & VolatilityBeta, volatility, and downside exposure
CHNR2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
CHNR leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
SXTC and CHNR operate at a comparable scale, with $2M and $0 in trailing revenue.
| Metric | SXTCChina SXT Pharmac… | CHNRChina Natural Res… |
|---|---|---|
| RevenueTrailing 12 months | $2M | $0 |
| EBITDAEarnings before interest/tax | -$3M | -$12M |
| Net IncomeAfter-tax profit | -$3M | -$14M |
| Free Cash FlowCash after capex | -$2M | -$6M |
| Gross MarginGross profit ÷ Revenue | +21.1% | — |
| Operating MarginEBIT ÷ Revenue | -154.0% | — |
| Net MarginNet income ÷ Revenue | -189.8% | — |
| FCF MarginFCF ÷ Revenue | -134.8% | — |
| Rev. Growth (YoY)Latest quarter vs prior year | -7.8% | — |
| EPS Growth (YoY)Latest quarter vs prior year | -119.1% | +91.3% |
CHNR leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — SXTC and CHNR each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | SXTCChina SXT Pharmac… | CHNRChina Natural Res… |
|---|---|---|
| Market CapShares × price | $670,507 | $42M |
| Enterprise ValueMkt cap + debt − cash | -$16M | $41M |
| Trailing P/EPrice ÷ TTM EPS | -0.20x | -88.68x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 0.39x | — |
| Price / BookPrice ÷ Book value/share | 0.04x | 3.21x |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — SXTC and CHNR each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
CHNR leads this category, winning 5 of 8 comparable metrics.
Profitability & Efficiency
CHNR delivers a -15.7% return on equity — every $100 of shareholder capital generates $-16 in annual profit, vs $-21 for SXTC. On the Piotroski fundamental quality scale (0–9), SXTC scores 4/9 vs CHNR's 2/9, reflecting mixed financial health.
| Metric | SXTCChina SXT Pharmac… | CHNRChina Natural Res… |
|---|---|---|
| ROE (TTM)Return on equity | -21.4% | -15.7% |
| ROA (TTM)Return on assets | -15.2% | -5.3% |
| ROICReturn on invested capital | -142.0% | -0.0% |
| ROCEReturn on capital employed | -17.9% | -0.0% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 2 |
| Debt / EquityFinancial leverage | 0.06x | — |
| Net DebtTotal debt minus cash | -$17M | -$3M |
| Cash & Equiv.Liquid assets | $18M | $3M |
| Total DebtShort + long-term debt | $983,877 | $0 |
| Interest CoverageEBIT ÷ Interest expense | -4.14x | -263.29x |
CHNR leads this category, winning 5 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
CHNR leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in CHNR five years ago would be worth $721 today (with dividends reinvested), compared to $4 for SXTC. Over the past 12 months, CHNR leads with a -2.3% total return vs SXTC's -99.4%. The 3-year compound annual growth rate (CAGR) favors CHNR at -41.2% vs SXTC's -87.6% — a key indicator of consistent wealth creation.
| Metric | SXTCChina SXT Pharmac… | CHNRChina Natural Res… |
|---|---|---|
| YTD ReturnYear-to-date | -99.4% | +22.2% |
| 1-Year ReturnPast 12 months | -99.4% | -2.3% |
| 3-Year ReturnCumulative with dividends | -99.8% | -79.7% |
| 5-Year ReturnCumulative with dividends | -100.0% | -92.8% |
| 10-Year ReturnCumulative with dividends | -100.0% | -93.5% |
| CAGR (3Y)Annualised 3-year return | -87.6% | -41.2% |
CHNR leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
CHNR leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
CHNR is the less volatile stock with a 1.12 beta — it tends to amplify market swings less than SXTC's 1.16 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CHNR currently trades 52.4% from its 52-week high vs SXTC's 0.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | SXTCChina SXT Pharmac… | CHNRChina Natural Res… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.16x | 1.12x |
| 52-Week HighHighest price in past year | $1046.98 | $8.20 |
| 52-Week LowLowest price in past year | $0.08 | $3.16 |
| % of 52W HighCurrent price vs 52-week peak | +0.2% | +52.4% |
| RSI (14)Momentum oscillator 0–100 | 30.7 | 55.2 |
| Avg Volume (50D)Average daily shares traded | 55K | 893K |
CHNR leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | SXTCChina SXT Pharmac… | CHNRChina Natural Res… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | — |
| Price TargetConsensus 12-month target | — | — |
| # AnalystsCovering analysts | — | — |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | 0 |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
CHNR leads in 4 of 6 categories — strongest in Income & Cash Flow and Profitability & Efficiency. 1 category is tied.
Best OverallChina Natural Resources, In… (CHNR)Leads 4 of 6 categories
Loading custom metrics...
SXTC vs CHNR: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Which is the better long-term investment — SXTC or CHNR?
Over the past 5 years, China Natural Resources, Inc.
(CHNR) delivered a total return of -92. 8%, compared to -100. 0% for China SXT Pharmaceuticals, Inc. (SXTC). Over 10 years, the gap is even starker: CHNR returned -93. 5% versus SXTC's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
02Which is safer — SXTC or CHNR?
By beta (market sensitivity over 5 years), China Natural Resources, Inc.
(CHNR) is the lower-risk stock at 1. 12β versus China SXT Pharmaceuticals, Inc. 's 1. 16β — meaning SXTC is approximately 4% more volatile than CHNR relative to the S&P 500.
03Which is growing faster — SXTC or CHNR?
On earnings-per-share growth, the picture is similar: China Natural Resources, Inc.
grew EPS 95. 9% year-over-year, compared to -129. 1% for China SXT Pharmaceuticals, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
04Which has better profit margins — SXTC or CHNR?
China Natural Resources, Inc.
(CHNR) is the more profitable company, earning 0. 0% net margin versus -189. 8% for China SXT Pharmaceuticals, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CHNR leads at 0. 0% versus -154. 0% for SXTC. At the gross margin level — before operating expenses — SXTC leads at 21. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — SXTC or CHNR?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
06Is SXTC or CHNR better for a retirement portfolio?
For long-horizon retirement investors, China Natural Resources, Inc.
(CHNR) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 12)). Both have compounded well over 10 years (CHNR: -93. 5%, SXTC: -100. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between SXTC and CHNR?
These companies operate in different sectors (SXTC (Healthcare) and CHNR (Industrials)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.